Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Dose-Dependent Sorafenib-Induced Immunosuppression Is Associated with Aberrant NFAT Activation and Expression of PD-1 in T Cells.

Iyer RV, Maguire O, Kim M, Curtin LI, Sexton S, Fisher DT, Schihl SA, Fetterly G, Menne S, Minderman H.

Cancers (Basel). 2019 May 16;11(5). pii: E681. doi: 10.3390/cancers11050681.

2.

A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients.

Ma WW, Xie H, Fetterly G, Pitzonka L, Whitworth A, LeVea C, Wilton J, Mantione K, Schihl S, Dy GK, Boland P, Iyer R, Tan W, Brady W, Straubinger RM, Adjei AA.

Am J Clin Oncol. 2019 Feb;42(2):184-189. doi: 10.1097/COC.0000000000000492.

PMID:
30418178
3.

A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies.

Fountzilas C, Javle M, Tan W, Ma Y, Fetterly G, Iyer R, Johnson C.

Cancer. 2018 Oct 1;124(19):3890-3899. doi: 10.1002/cncr.31676. Epub 2018 Oct 9.

PMID:
30299542
4.

Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361).

Smolinski MP, Bu Y, Clements J, Gelman IH, Hegab T, Cutler DL, Fang JWS, Fetterly G, Kwan R, Barnett A, Lau JYN, Hangauer DG.

J Med Chem. 2018 Jun 14;61(11):4704-4719. doi: 10.1021/acs.jmedchem.8b00164. Epub 2018 Apr 17.

PMID:
29617135
5.

Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study.

Ramanathan RK, Korn RL, Raghunand N, Sachdev JC, Newbold RG, Jameson G, Fetterly GJ, Prey J, Klinz SG, Kim J, Cain J, Hendriks BS, Drummond DC, Bayever E, Fitzgerald JB.

Clin Cancer Res. 2017 Jul 15;23(14):3638-3648. doi: 10.1158/1078-0432.CCR-16-1990. Epub 2017 Feb 3.

6.

Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma.

Nair JR, Caserta J, Belko K, Howell T, Fetterly G, Baldino C, Lee KP.

Leukemia. 2017 Aug;31(8):1715-1726. doi: 10.1038/leu.2016.379. Epub 2016 Dec 23.

7.

Development and verification of a pharmacokinetic model to optimize physiologic replacement of rhIGF-1/rhIGFBP-3 in preterm infants.

Chung JK, Hallberg B, Hansen-Pupp I, Graham MA, Fetterly G, Sharma J, Tocoian A, Kreher NC, Barton N, Hellström A, Ley D.

Pediatr Res. 2017 Mar;81(3):504-510. doi: 10.1038/pr.2016.255. Epub 2016 Nov 21.

PMID:
27870826
8.

Bridging Sunitinib Exposure to Time-to-Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker.

Ait-Oudhia S, Mager DE, Pokuri V, Tomaszewski G, Groman A, Zagst P, Fetterly G, Iyer R.

CPT Pharmacometrics Syst Pharmacol. 2016 Jun;5(6):297-304. doi: 10.1002/psp4.12084. Epub 2016 Jun 8.

9.

Efficacy, Safety, and Potential Biomarkers of Sunitinib and Transarterial Chemoembolization (TACE) Combination in Advanced Hepatocellular Carcinoma (HCC): Phase II Trial.

Pokuri VK, Tomaszewski GM, Ait-Oudhia S, Groman A, Khushalani NI, Lugade AA, Thanavala Y, Ashton EA, Grande C, Fetterly GJ, Iyer R.

Am J Clin Oncol. 2018 Apr;41(4):332-338. doi: 10.1097/COC.0000000000000286.

PMID:
27014931
10.

Tumor priming by Apo2L/TRAIL reduces interstitial fluid pressure and enhances efficacy of liposomal gemcitabine in a patient derived xenograft tumor model.

Hylander BL, Sen A, Beachy SH, Pitoniak R, Ullas S, Gibbs JF, Qiu J, Prey JD, Fetterly GJ, Repasky EA.

J Control Release. 2015 Nov 10;217:160-9. doi: 10.1016/j.jconrel.2015.08.047. Epub 2015 Sep 3.

11.

Phase 1b study of the oral gemcitabine 'Pro-drug' LY2334737 in combination with capecitabine in patients with advanced solid tumors.

Infante JR, Benhadji KA, Dy GK, Fetterly G, Ma WW, Bendell J, Callies S, Adjei AA.

Invest New Drugs. 2015 Apr;33(2):432-9. doi: 10.1007/s10637-015-0207-9. Epub 2015 Feb 3.

PMID:
25640850
12.

Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.

Adelaiye R, Ciamporcero E, Miles KM, Sotomayor P, Bard J, Tsompana M, Conroy D, Shen L, Ramakrishnan S, Ku SY, Orillion A, Prey J, Fetterly G, Buck M, Chintala S, Bjarnason GA, Pili R.

Mol Cancer Ther. 2015 Feb;14(2):513-22. doi: 10.1158/1535-7163.MCT-14-0208. Epub 2014 Dec 17.

13.

Influence of sex and race on mycophenolic acid pharmacokinetics in stable African American and Caucasian renal transplant recipients.

Tornatore KM, Meaney CJ, Wilding GE, Chang SS, Gundroo A, Cooper LM, Gray V, Shin K, Fetterly GJ, Prey J, Clark K, Venuto RC.

Clin Pharmacokinet. 2015 Apr;54(4):423-34. doi: 10.1007/s40262-014-0213-7.

14.

Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs.

Wilton J, Kurenova E, Pitzonka L, Gaudy A, Curtin L, Sexton S, Cance W, Fetterly G.

Eur J Drug Metab Pharmacokinet. 2016 Feb;41(1):55-67. doi: 10.1007/s13318-014-0233-6. Epub 2014 Nov 7.

15.

A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors.

Ngamphaiboon N, Dy GK, Ma WW, Zhao Y, Reungwetwattana T, DePaolo D, Ding Y, Brady W, Fetterly G, Adjei AA.

Invest New Drugs. 2015 Feb;33(1):225-32. doi: 10.1007/s10637-014-0174-6. Epub 2014 Nov 5.

PMID:
25371323
16.

Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens.

Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RZ, Friedlander TW, Fong L, Lin AM, Harzstark AL, Molina A, Small EJ, Ryan CJ.

Clin Cancer Res. 2014 Dec 15;20(24):6269-76. doi: 10.1158/1078-0432.CCR-14-1595. Epub 2014 Oct 21.

17.
18.

A pilot study comparing the effect of flaxseed, aromatase inhibitor, and the combination on breast tumor biomarkers.

McCann SE, Edge SB, Hicks DG, Thompson LU, Morrison CD, Fetterly G, Andrews C, Clark K, Wilton J, Kulkarni S.

Nutr Cancer. 2014;66(4):566-75. doi: 10.1080/01635581.2014.894097. Epub 2014 Mar 26.

19.

Carboplatin pharmacokinetics in a patient receiving hemodialysis.

Fong MK, Fetterly GJ Jr, McDougald LJ, Iyer RV.

Pharmacotherapy. 2014 Feb;34(2):e9-13. doi: 10.1002/phar.1354. Epub 2013 Sep 14.

20.

Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data.

Fetterly GJ, Aras U, Meholick PD, Takimoto C, Seetharam S, McIntosh T, de Bono JS, Sandhu SK, Tolcher A, Davis HM, Zhou H, Puchalski TA.

J Clin Pharmacol. 2013 Oct;53(10):1020-7. doi: 10.1002/jcph.140. Epub 2013 Jul 23.

PMID:
23878055
21.

Development of a preclinical PK/PD model to assess antitumor response of a sequential aflibercept and doxorubicin-dosing strategy in acute myeloid leukemia.

Fetterly GJ, Aras U, Lal D, Murphy M, Meholick PD, Wang ES.

AAPS J. 2013 Jul;15(3):662-73. doi: 10.1208/s12248-013-9480-8. Epub 2013 Apr 3.

22.

Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice.

Pawaskar DK, Straubinger RM, Fetterly GJ, Hylander BH, Repasky EA, Ma WW, Jusko WJ.

Cancer Chemother Pharmacol. 2013 May;71(5):1231-40. doi: 10.1007/s00280-013-2117-x. Epub 2013 Mar 3.

23.

Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.

Pawaskar DK, Straubinger RM, Fetterly GJ, Hylander BH, Repasky EA, Ma WW, Jusko WJ.

Cancer Chemother Pharmacol. 2013 May;71(5):1219-29. doi: 10.1007/s00280-013-2116-y. Epub 2013 Mar 3.

24.

A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies.

Naing A, Cohen R, Dy GK, Hong DS, Dyster L, Hangauer DG, Kwan R, Fetterly G, Kurzrock R, Adjei AA.

Invest New Drugs. 2013 Aug;31(4):967-73. doi: 10.1007/s10637-013-9929-8. Epub 2013 Jan 30.

PMID:
23361621
25.

A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.

Antonarakis ES, Heath EI, Posadas EM, Yu EY, Harrison MR, Bruce JY, Cho SY, Wilding GE, Fetterly GJ, Hangauer DG, Kwan MF, Dyster LM, Carducci MA.

Cancer Chemother Pharmacol. 2013 Apr;71(4):883-92. doi: 10.1007/s00280-013-2079-z. Epub 2013 Jan 13.

26.

Interactions of everolimus and sorafenib in whole blood lymphocyte proliferation.

Pawaskar DK, Straubinger RM, Fetterly GJ, Ma WW, Jusko WJ.

Pharm Res. 2013 Mar;30(3):707-13. doi: 10.1007/s11095-012-0909-z. Epub 2012 Nov 14.

27.

Interactions of everolimus and sorafenib in pancreatic cancer cells.

Pawaskar DK, Straubinger RM, Fetterly GJ, Ma WW, Jusko WJ.

AAPS J. 2013 Jan;15(1):78-84. doi: 10.1208/s12248-012-9417-7. Epub 2012 Oct 9.

28.

Synergism between clofarabine and decitabine through p53R2: a pharmacodynamic drug-drug interaction modeling.

Thudium KE, Ghoshal S, Fetterly GJ, Haese JP, Karpf AR, Wetzler M.

Leuk Res. 2012 Nov;36(11):1410-6. doi: 10.1016/j.leukres.2012.07.015. Epub 2012 Aug 9.

29.

A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer.

Weickhardt A, Doebele R, Oton A, Lettieri J, Maxson D, Reynolds M, Brown A, Jackson MK, Dy G, Adjei A, Fetterly G, Lu X, Franklin W, Varella-Garcia M, Hirsch FR, Wynes MW, Youssoufian H, Adjei A, Camidge DR.

J Thorac Oncol. 2012 Feb;7(2):419-26. doi: 10.1097/JTO.0b013e31823c5b11.

30.

Methyl selenocysteine: single-dose pharmacokinetics in men.

Marshall JR, Ip C, Romano K, Fetterly G, Fakih M, Jovanovic B, Perloff M, Crowell J, Davis W, French-Christy R, Dew A, Coomes M, Bergan R.

Cancer Prev Res (Phila). 2011 Nov;4(11):1938-44. doi: 10.1158/1940-6207.CAPR-10-0259. Epub 2011 Aug 16.

31.

Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas.

Brem EA, Thudium K, Khubchandani S, Tsai PC, Olejniczak SH, Bhat S, Riaz W, Gu J, Iqbal A, Campagna R, Knight J, Mavis C, Hoskin P, Deeb G, Gibbs JF, Fetterly G, Czuczman MS, Hernandez-Ilizaliturri FJ.

Br J Haematol. 2011 Jun;153(5):599-611. doi: 10.1111/j.1365-2141.2011.08669.x. Epub 2011 Apr 15.

32.

Aflibercept exerts antivascular effects and enhances levels of anthracycline chemotherapy in vivo in human acute myeloid leukemia models.

Lal D, Park JA, Demock K, Marinaro J, Perez AM, Lin MH, Tian L, Mashtare TJ, Murphy M, Prey J, Wetzler M, Fetterly GJ, Wang ES.

Mol Cancer Ther. 2010 Oct;9(10):2737-51. doi: 10.1158/1535-7163.MCT-10-0334. Epub 2010 Oct 5.

33.

Sorafenib: a clinical and pharmacologic review.

Iyer R, Fetterly G, Lugade A, Thanavala Y.

Expert Opin Pharmacother. 2010 Aug;11(11):1943-55. doi: 10.1517/14656566.2010.496453. Review.

PMID:
20586710
34.

A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors.

Fakih MG, Fetterly G, Egorin MJ, Muindi JR, Espinoza-Delgado I, Zwiebel JA, Litwin A, Holleran JL, Wang K, Diasio RB.

Clin Cancer Res. 2010 Jul 15;16(14):3786-94. doi: 10.1158/1078-0432.CCR-10-0547. Epub 2010 May 12.

35.

Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants.

Tummala R, Diegelman P, Hector S, Kramer DL, Clark K, Zagst P, Fetterly G, Porter CW, Pendyala L.

Cancer Chemother Pharmacol. 2011 Feb;67(2):401-14. doi: 10.1007/s00280-010-1334-9. Epub 2010 May 5.

36.

A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer.

Fakih MG, Pendyala L, Fetterly G, Toth K, Zwiebel JA, Espinoza-Delgado I, Litwin A, Rustum YM, Ross ME, Holleran JL, Egorin MJ.

Clin Cancer Res. 2009 May 1;15(9):3189-95. doi: 10.1158/1078-0432.CCR-08-2999. Epub 2009 Apr 21.

37.

Erlotinib for metastatic non-small-cell lung cancer: first-, second- or third-line setting - does it matter ? A single-institution experience.

Ailawadhi S, Derby L, Natarajan R, Fetterly G, Reid M, Ramnath N.

Oncology. 2009;76(2):85-90. doi: 10.1159/000187427. Epub 2008 Dec 20.

PMID:
19122466
38.

Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel.

Fetterly GJ, Grasela TH, Sherman JW, Dul JL, Grahn A, Lecomte D, Fiedler-Kelly J, Damjanov N, Fishman M, Kane MP, Rubin EH, Tan AR.

Clin Cancer Res. 2008 Sep 15;14(18):5856-63. doi: 10.1158/1078-0432.CCR-08-1046.

39.

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.

Mita MM, Mita AC, Chu QS, Rowinsky EK, Fetterly GJ, Goldston M, Patnaik A, Mathews L, Ricart AD, Mays T, Knowles H, Rivera VM, Kreisberg J, Bedrosian CL, Tolcher AW.

J Clin Oncol. 2008 Jan 20;26(3):361-7. doi: 10.1200/JCO.2007.12.0345.

PMID:
18202410
40.

Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment.

Fetterly GJ, Owen JS, Stuyckens K, Passarell JA, Zannikos P, Soto-Matos A, Izquierdo MA, Perez-Ruixo JJ.

Cancer Chemother Pharmacol. 2008 Jun;62(1):135-47. Epub 2007 Oct 9.

PMID:
17922277
41.

Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose.

Fetterly GJ, Ong CM, Bhavnani SM, Loutit JS, Porter SB, Morello LG, Ambrose PG, Nicolau DP.

Antimicrob Agents Chemother. 2005 Jan;49(1):148-52.

42.

Pharmacokinetics of paclitaxel-containing liposomes in rats.

Fetterly GJ, Straubinger RM.

AAPS PharmSci. 2003 Nov 21;5(4):E32.

43.

Noncovalent dimerization of paclitaxel in solution: evidence from electrospray ionization mass spectrometry.

Lorenz SA, Bigwarfe PM Jr, Balasubramanian SV, Fetterly GJ, Straubinger RM, Wood TD.

J Pharm Sci. 2002 Sep;91(9):2057-66.

PMID:
12210052
44.

Paclitaxel pharmacodynamics: application of a mechanism-based neutropenia model.

Fetterly GJ, Tamburlin JM, Straubinger RM.

Biopharm Drug Dispos. 2001 Sep;22(6):251-61.

PMID:
11754041

Supplemental Content

Loading ...
Support Center